跳至主要内容
临床试验/ACTRN12615000759594
ACTRN12615000759594招募中2 期

Effect of angioplasty and stenting versus aggressive medical treatment on mortality and stroke in patients with symptomatic intracranial artery stenosis: a randomized controlled trial and a preference cohort

Fuzhou General Hospital of Nanjing Command, PLA and clinical medical college of Fujian medical university0 个研究点目标入组 198 人开始时间: 2015年7月21日最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
198

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • 1. Patients aged from 18 to 70 years.
  • 2. Complaints of a Symptomatic ICAS: a history of recurrent transient ischemic attacks or an ischemic stroke within 1 year owing to a stenosis from 70% to 99% in an internal carotid artery, middle cerebral artery, vertebral artery, or basilar artery.
  • 3. A length less than or equal to 15mm of a stenosis in the target vessel and a vessel size greater than or equal to 2mm.
  • 4. Hypoperfusion in the territory of the target vessels, which is determined by CT or MRI in 14 days before stenting.
  • 5. CT or MRI scans show no massive cerebral infarction (beyond half of the MCA territory), intracranial hemorrhage, epidural or sub-dural hemorrhage, and intracranial brain tumor.
  • 6. Patients who understand the purpose of the study and have provided informed consent.

排除标准

  • 1. Not able to receive general anesthesia.
  • 2. Not able to receive angiographic assessment.
  • 3. A stenosis >50% in an extracranial carotid or vertebral artery on the ipsilateral side.
  • 4. Infarctions due to the perforators occlusion (determined by MRI scan), which is defined as basal ganglia or brainstem/thalamus infarction related with middle cerebral artery or basilar artery stenosis.
  • 5. A high risk (leading to a stroke or death) to deliver the stent to the lesion.
  • 6. A previous stent or angioplasty in the target lesion.
  • 7. Progressive neurological signs within 24 hours before enrolment
  • 8. Any haemorrhagic infarct within 14 days before enrolment
  • 9. The presence of a cardiac source of embolus
  • 10. Thrombolytic therapy within 24 hours before enrollment
  • 11. Presence of intraluminal thrombus proximal to or at the target lesion
  • 12. Myocardial infarction within previous 30 days
  • 13. Non-atherosclerotic lesions: arterial dissection, moya-moya disease; vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with cerebrospinal fluid pleocytosis; radiation-induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; postpartum angiopathy; suspected vasospastic process, and suspected recanalized embolus.
  • 14. Known contraindications for aspirin and clopidogrel treatment.
  • 15. An modified Rankin score greater than or equal to 3.
  • 16. With a childbearing potential or a positive pregnancy test in 1 week before enrolment.

研究者

发起方
Fuzhou General Hospital of Nanjing Command, PLA and clinical medical college of Fujian medical university

相似试验